Sustained brain response to repeated drug cues is associated with poor drug‐use outcomes

2021 ◽  
Author(s):  
Paul S. Regier ◽  
Kanchana Jagannathan ◽  
Teresa R. Franklin ◽  
Reagan R. Wetherill ◽  
Daniel D. Langleben ◽  
...  
Keyword(s):  
Drug Use ◽  
Brain Response ◽  
Drug Cues ◽  
Drug Use Outcomes

Client commitment language during motivational interviewing predicts drug use outcomes.

2003 ◽  
Vol 71 (5) ◽  
pp. 862-878 ◽  
Author(s):  
Paul C. Amrhein ◽  
William R. Miller ◽  
Carolina E. Yahne ◽  
Michael Palmer ◽  
Laura Fulcher
Keyword(s):  
Drug Use ◽  
Motivational Interviewing ◽  
Drug Use Outcomes

scholarly journals Feasibility and Preliminary Efficacy of Isradipine During Outpatient Buprenorphine Stabilization and Detoxification: A Pilot Randomized, Placebo-Controlled Trial

2020 ◽  
Vol 14 ◽  
pp. 117822182097092
Author(s):  
Nihit Kumar ◽  
Michael J Mancino ◽  
Jeff D Thostenson ◽  
Janette McGaugh ◽  
Alison H Oliveto
Keyword(s):  
Drug Use ◽  
Medication Compliance ◽  
Controlled Trial ◽  
Pilot Trial ◽  
Vital Signs ◽  
Immediate Release ◽  
Clinic Visit ◽  
Opioid Use ◽  
Release Formulation ◽  
Drug Use Outcomes

Background: Given the immense burden of the widespread use of opioids around the world, exploring treatments that improve drug use outcomes, and craving and withdrawal measures in individuals with opioid use disorder is crucial. This pilot study examined the feasibility and preliminary efficacy of the L-type calcium-channel blocker isradipine (ISR) to improve drug use outcomes, and craving and withdrawal measures during buprenorphine (BUP)/ISR stabilization and subsequent taper in opioid-dependent individuals. Methods: Participants were stabilized on BUP sublingual tablets within the first 2 days of week 1, were then randomized and inducted on either ISR or placebo, gradually increasing the dose over the next 2 weeks, followed by a 10-day BUP taper during weeks 5-6, and ISR/placebo taper during weeks 7 to 8. Assessments included thrice-weekly measures of craving and withdrawal, as well as vital signs and urine drug screens. Medication compliance was assessed by monitoring number of missed clinic visit days. Results: Baseline characteristics of participants (n = 25; 60% male, 96% Caucasian, 48% employed, mean age 32.8 years) did not differ significantly between treatment groups (isradipine, n = 11; placebo, n = 14). During the stabilization phase (n = 19), ISR participants had significantly lower rates of illicit opioid-positive urines (treatment × visit: t = -2.16, P = 0.03), as well as reduction in craving intensity ( t = –2.50, P = 0.01), frequency ( t = –3.43, P < 0.01) and duration ( t = –2.51, P = 0.01). ISR was well tolerated with mild adverse effects. Conclusions: This study was likely underpowered due to being a pilot trial. Although preliminary results suggest ISR may improve BUP-assisted treatment outcomes, concerns about high number of exclusions (n = 11 during taper phase) based on cardiovascular measures as well as ISR-induced changes in vital signs with the immediate release formulation may limit the feasibility of this approach. Trial Registration: Clinicaltrials.gov identifier NCT01895270. Registered 10 July 2013, https://clinicaltrials.gov/ct2/show/NCT01895270?id=NCT01895270&draw=2&rank=1

Different vulnerabilities for addiction may contribute to the same phenomena and some additional interactions

2008 ◽  
Vol 31 (4) ◽  
pp. 445-446 ◽  
Author(s):  
Andrew James Goudie ◽  
Matt Field ◽  
Jon Cole
Keyword(s):  
Drug Use ◽  
Attentional Bias ◽  
Delay Discounting ◽  
Real World ◽  
Probability Discounting ◽  
Drug Cues ◽  
Target Article ◽  
Motivational Salience

AbstractThe framework for addiction offered by the target article can perhaps be simplified into fewer, more basic, vulnerabilities. “Impulsivity” covers a number of vulnerabilities, not just enhanced delay discounting. Real-world drug-use decisions involve both delay and probability discounting. The motivational salience of, and attentional bias for, drug cues may be related to a number of vulnerabilities. Interactions among vulnerabilities are of significance and complicate the application of this framework.

Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project

2012 ◽  
Vol 39 (2) ◽  
pp. 221-226 ◽  
Author(s):  
Paolo Deluca ◽  
Zoe Davey ◽  
Ornella Corazza ◽  
Lucia Di Furia ◽  
Magi Farre ◽  
...  
Keyword(s):  
Drug Use ◽  
Recreational Drug ◽  
Web Mapping ◽  
Emerging Trends ◽  
Recreational Drug Use ◽  
Drug Use Outcomes

Extended-release naltrexone modulates brain response to drug cues in abstinent heroin-dependent patients

2012 ◽  
Vol 19 (2) ◽  
pp. 262-271 ◽  
Author(s):  
Daniel D. Langleben ◽  
Kosha Ruparel ◽  
Igor Elman ◽  
James W. Loughead ◽  
Elliot L. Busch ◽  
...  
Keyword(s):  
Extended Release ◽  
Brain Response ◽  
Drug Cues
Sign in / Sign up

Export Citation Format

Share Document